A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma (Q42647126)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma |
scientific article |
Statements
1 reference
A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma (English)
1 reference
Peter Hersey
1 reference
Jeffrey Sosman
1 reference
Steven O'Day
1 reference
Jon Richards
1 reference
Agop Bedikian
1 reference
Rene Gonzalez
1 reference
William Sharfman
1 reference
Robert Weber
1 reference
Theodore Logan
1 reference
Manuela Buzoianu
1 reference
Luz Hammershaimb
1 reference
John M Kirkwood
1 reference
Etaracizumab Melanoma Study Group
1 reference
1 March 2010
1 reference
Identifiers
1 reference